have a larger footprint in ground operations. FedEx recently extended its alliance with healthcare products provider Cardinal Health , a multi-billion dollar healthcare services company, to expand its healthcare shipment services. In this note
Equalweight at Morgan Stanley. Sorrento Therapeutics ( SRNE ) started at Buy at CRT Capital. Price target is $11. Cardinal Health ( CAH ) initiated at Hold at Deutsche Bank. Price target is $66. Charles River Labs ( CRL ) started at Hold at Deutsche
navigating CareFusion through its spin-off from Cardinal Health in August 2009. Kieran Gallahue, previously CEO ..... changing of the guard. James Hinrichs, who joined Cardinal Health in 2004, assumed the CFO position. CareFusion has
Cardinal Health Inc . ( CAH ) declares $0.3025/share quarterly dividend , in line with previous. Forward yield 1.98% Payable Jan 15; for shareholders of record Jan 2; ex-div Dec. 30. Post your comment!
upgraded to Hold at Janney , Cantor , and Needham . Piper upgrades the shares to Neutral from Underweight. Cardinal Health ( CAH ) upgraded to Buy from Neutral at Sterne Agee. Dendreon ( DNDN ) initiated at Fairly Valued by CRT Capital
Cardinal Health ( CAH ) is upgraded by Sterne Agee to a Buy rating. The investment firm raises its price target on the healthcare services firm to $273. CAH +0.9% premarket to $61.09 Post your comment!
FBR starts McKesson ( MCK +0.9% ) and Cardinal Health ( CAH +1.2% ) at Outperform and AmerisourceBergen ( ABC +0.5% ) at Market Perform . Post your comment!
capital. Papa, who became CEO of Perrigo in 2006, previously led the pharmaceutical and technologies segment of Cardinal Health CAH and was COO of Watson Pharmaceuticals WPI. In addition to Papa's dual role as CEO and chairman, the board also
Schein is a much smaller player in the medical distribution market where it faces larger peers like McKesson MCK and Cardinal Health CAH . In the dental and companion animal health segments, Schein's distribution and services cater to nearly every
mandates will most likely build in more competition and less profitability into the sector. We will watch closely how Cardinal Health handles the changing environment as we transfer coverage and evaluate our long-term analysis of the pharmaceutical